Overview

Study of Radiolabeled SNDX-5613 in Adults With Acute Myeloid Leukemia

Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label study to study the absorption, metabolism, and excretion (AME) of carbon-14 ([14C])-SNDX-5613 in adult males with acute myeloid leukemia (AML).
Phase:
Phase 1
Details
Lead Sponsor:
Syndax Pharmaceuticals